Ivan R. González, Medical Oncologist at the Comprehensive Cancer Center, Hospital Ángeles Puebla, shared a post on X:

“Interesting results from the phase III MECCA trial for the initial treatment of HR+ HER2- metastatic breast cancer:

Results:

– PFS: 20.9 months (metronomic capecitabine + AI) vs. 11.9 months (AI).
– HR: 0.58 (95% CI, 0.43-0.76).
– OS: Not reached vs. 45.1 months.
– HR: 0.58 (95% CI, 0.37-0.93).

Adverse events:

– Grade 3: 15.1% (palmar-plantar erythrodysesthesia, peripheral neuropathy).

Metronomic capecitabine + AI significantly improves PFS and OS with a tolerable safety profile.”

Ashish Singh, Professor of Medical Oncology at Christian Medical College Vellore India, shared this post, adding:

“Capecitabine has been a consistent performer across all stages of breast cancer..

also commonly ignored as a control arm option in many of the recent MBC clinical trials.”

Metronomic Capecitabine Plus Aromatase Inhibitor as Initial Therapy in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer—The Phase III MECCA Trial

Authors: Ruo-Xi Hong et al.

Ivan R. González

Ivan R. González: Interesting results from the phase III MECCA trial